SEC Form SC 13G filed by Dicerna Pharmaceuticals, Inc.

SEC Form SC 13G filed by Dicerna Pharmaceuticals, Inc.

Recent Analyst Ratings for $DRNA

$DRNA Insider Trading

$DRNA Large Ownership Changes

$DRNA Analyst Ratings

$DRNA Press Releases

$DRNA Financials

$DRNA SEC Filings

$DRNA Leadership Updates

$DRNA Market Insights

Recent Analyst Ratings for
$DRNA

$DRNA
Insider Trading

$DRNA
Large Ownership Changes

$DRNA
Analyst Ratings

$DRNA
Press Releases

$DRNA
Financials

$DRNA
SEC Filings

$DRNA
Leadership Updates

$DRNA
Market Insights

Chat with this insight

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Koppel Adam closing all direct ownership in the company

SEC Form 4: Zeng Ling closing all direct ownership in the company

SEC Form 4: Weissman James B closing all direct ownership in the company

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Dicerna Pharmaceuticals, Inc.

SEC Form SC 13G/A filed

SEC Form SC 13G/A filed

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Dicerna Pharmaceuticals downgraded by Chardan Capital with a new price target

Dicerna Pharmaceuticals downgraded by RBC Capital with a new price target

Dicerna Pharmaceuticals downgraded by HC Wainwright & Co. with a new price target

Fastest customizable press release news feed in the world

Live finance-specific insights

Live Leadership Updates

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna

Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update

Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021

SEC Form 15-12B filed by Dicerna Pharmaceuticals, Inc.

SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.

SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Dicerna Announces New Executive Leadership Appointments

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Live Market Insights

10 Biggest Price Target Changes For Thursday

Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021

Chardan Capital Downgrades Dicerna Pharmaceuticals to Neutral, Raises Price Target to $38.25

12/3/21 6:09:54 AM ET

$DRNA

Major Pharmaceuticals

Health Care

Get the next $DRNA alert in real time by email

SC 13G 1 d161089dsc13g.htm SC 13G SC 13G

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

Dicerna Pharmaceuticals Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

253031108

(CUSIP Number)

November 23, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 253031108		Page 2 of 29 Pages

*SEE INSTRUCTIONS BEFORE FILLING OUT.


CUSIP No. 253031108		Page 3 of 29 Pages

*SEE INSTRUCTIONS BEFORE FILLING OUT.


CUSIP No. 253031108		Page 4 of 29 Pages

*SEE INSTRUCTIONS BEFORE FILLING OUT.


CUSIP No. 253031108		Page 5 of 29 Pages

*SEE INSTRUCTIONS BEFORE FILLING OUT.


CUSIP No. 253031108		Page 6 of 29 Pages

*SEE INSTRUCTIONS BEFORE FILLING OUT.


CUSIP No. 253031108		Page 7 of 29 Pages

*SEE INSTRUCTIONS BEFORE FILLING OUT.


CUSIP No. 253031108		Page 8 of 29 Pages

*SEE INSTRUCTIONS BEFORE FILLING OUT.


CUSIP No. 253031108		Page 9 of 29 Pages

*SEE INSTRUCTIONS BEFORE FILLING OUT.


CUSIP No. 253031108		Page 10 of 29 Pages

*SEE INSTRUCTIONS BEFORE FILLING OUT.


CUSIP No. 253031108		Page 11 of 29 Pages

*SEE INSTRUCTIONS BEFORE FILLING OUT.


CUSIP No. 253031108		Page 12 of 29 Pages

*SEE INSTRUCTIONS BEFORE FILLING OUT.


CUSIP No. 253031108		Page 13 of 29 Pages

*SEE INSTRUCTIONS BEFORE FILLING OUT.


CUSIP No. 253031108		Page 14 of 29 Pages

*SEE INSTRUCTIONS BEFORE FILLING OUT.

Item 1 (a) Name of Issuer:

Dicerna Pharmaceuticals, Inc. (the “Company”)

(b)

Address of Issuer’s Principal Executive Offices:

87 Cambridgepark Drive

Cambridge, MA 02140

United States

Item 2 (a)

– (c) This statement is filed on behalf of the following:

(1) Atlas Diversified Master Fund, Ltd. is a Cayman corporation (“ADMF”), with its principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies.

(2) Atlas Diversified Fund, Ltd. is a Cayman corporation (“ADF LTD”), with its principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies. ADF LTD owns 96.88% of the equity interests in ADMF.

(3) Atlas Diversified Fund, L.P. is a Delaware limited partnership (“ADF LP”), with its principal business office at 444 West Lake Street, 50^th Floor, Chicago, IL 60606. ADF LP owns 3.12% of the equity interests in ADMF.

(4) Atlas Master Fund, Ltd. is a Cayman corporation (“AMF”), with its principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies.

(5)Atlas Global, LLC is a Delaware limited liability company (“AG”), with its principal business office at 444 West Lake Street, 50^th Floor, Chicago, IL 60606. AG owns 3.48% of the equity interests in AMF.

(6)Atlas Global Investments, Ltd. is a Cayman corporation (“AGI”), with its principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies. AGI owns 96.47% of the equity interests in AMF.

(7) Atlas Enhanced Master Fund, Ltd. is a Cayman corporation (“AEMF”), with its principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies.

Page 15 of 29 Pages

(8) Atlas Enhanced Fund, L.P. is a Delaware limited partnership (“AEF LP”), with its principal business office at 444 West Lake Street, 50^th Floor, Chicago, IL 60606. AEF LP owns 29.79% of the equity interests in AEMF.

(9) Atlas Enhanced Fund, Ltd. is a Cayman corporation (“AEF LTD”), with its principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies. AEF LTD owns 57.28% of the equity interests in AEMF.

(10) Atlas Portable Alpha, LP is a Delaware limited partnership (“APA LP”), with its principal business office at 444 West Lake Street, 50^th Floor, Chicago, IL 60606. APA LP owns 4.46% of the equity interests in AEMF.

(11) Atlas Terra Fund, Ltd. is a Cayman corporation (“ATF LTD”), with its principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies. ATF LTD owns 2.18% of the equity interests in AEMF.

(12) Atlas Institutional Equity Fund, L.P. is a Delaware limited partnership (“AIEF LP”), with its principal business office at 444 West Lake Street, 50^th Floor, Chicago, IL 60606. AIEF LP owns 6.28% of the equity interests in AEMF.

(13) Balyasny Asset Management L.P. is a Delaware limited partnership (“BAM”), with its principal business office at 444 West Lake Street, 50^th Floor, Chicago, IL 60606. BAM is the investment manager to each of ADMF, ADF LTD, ADF LP, AMF, AG, AGI, AEMF, AEF LP, AEF LTD, APA LP, ATF LTD and AIEF LP.

(14) Dmitry Balyasny, a United States citizen whose business address is 444 West Lake Street, 50^th Floor, Chicago, IL 60606. Dmitry Balyasny indirectly controls 100% of the general partner of BAM.

(d)

Title of Class of Securities:

Common Stock

(e)

CUSIP Number: 253031108

Item 3

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

Not Applicable

Page 16 of 29 Pages

Item 4

Ownership:

ADMF

(a)

Amount Beneficially Owned:

4,408,952

(b)

Percent of Class:

5.67%

(c)

Number of Shares as to which person has:

(i)

Sole power to vote or to direct vote:

4,408,952

(ii)

Shared power to vote or to direct vote:

None

(iii)

Sole power to dispose or direct disposition of:

4,408,952

(iv)

Shared power to dispose or to direct disposition of:

None

ADF LTD

(a)

Amount Beneficially Owned:

By virtue of its ownership of 96.88% of the equity interest in ADMF, ADF LTD may be deemed to beneficially own the 4,408,952 Shares of the Company’s Common Stock beneficially owned by ADMF.

(b)

Percent of Class:

5.67%

Page 17 of 29 Pages

(c)

Number of Shares as to which person has:

(i)

Sole power to vote or to direct vote:

4,408,952

(ii)

Shared power to vote or to direct vote:

None

(iii)

Sole power to dispose or direct disposition of:

4,408,952

(iv)

Shared power to dispose or to direct disposition of:

None

ADF LP

(a)

Amount Beneficially Owned:

By virtue of its ownership of 3.12% of the equity interest in ADMF, ADF LP may be deemed to beneficially own the 4,408,952 Shares of the Company’s Common Stock beneficially owned by ADMF.

(b)

Percent of Class:

5.67%

(c)

Number of Shares as to which person has:

(i)

Sole power to vote or to direct vote:

4,408,952

(ii)

Shared power to vote or to direct vote:

None

(iii)

Sole power to dispose or direct disposition of:

4,408,952

Page 18 of 29 Pages

(iv)

Shared power to dispose or to direct disposition of:

None

AMF

(a)

Amount Beneficially Owned:

By virtue of its ownership of 8.39% of the equity interest in ADMF, AMF may be deemed to beneficially own the 350,494 Shares of the Company’s Common Stock beneficially owned by ADMF.

(b)

Percent of Class:

0.45%

(c)

Number of Shares as to which person has:

(ii)

Sole power to vote or to direct vote:

350,494

(ii)

Shared power to vote or to direct vote:

None

(iii)

Sole power to dispose or direct disposition of:

350,494

(iv)

Shared power to dispose or to direct disposition of:

None

(a)

Amount Beneficially Owned:

By virtue of its ownership of 3.48% of the equity interest in AMF, AG may be deemed to beneficially own the 350,494 Shares of the Company’s Common Stock beneficially owned by ADMF.

Page 19 of 29 Pages

(b)

Percent of Class:

0.45%

(c)

Number of Shares as to which person has:

(i)

Sole power to vote or to direct vote:

350,494

(ii)

Shared power to vote or to direct vote:

None

(iii)

Sole power to dispose or direct disposition of:

350,494

(iv)

Shared power to dispose or to direct disposition of:

None

AGI

(a)

Amount Beneficially Owned:

By virtue of its ownership of 96.47% of the equity interest in AMF, AGI may be deemed to beneficially own the 350,494 Shares of the Company’s Common Stock beneficially owned by ADMF.

(b)

Percent of Class:

0.45%

(c)

Number of Shares as to which person has:

(i)

Sole power to vote or to direct vote:

350,494

(ii)

Shared power to vote or to direct vote:

None

(ii)

Sole power to dispose or direct disposition of:

350,494

Page 20 of 29 Pages

(iv)

Shared power to dispose or to direct disposition of:

None

AEMF

(a)

Amount Beneficially Owned:

By virtue of its ownership of 91.61% of the equity interest in ADMF, AEMF may be deemed to beneficially own the 3,997,346 Shares of the Company’s Common Stock beneficially owned by ADMF.

(b)

Percent of Class:

5.14%

(c)

Number of Shares as to which person has:

(i)

Sole power to vote or to direct vote:

3,997,346

(ii)

Shared power to vote or to direct vote:

None

(iii)

Sole power to dispose or direct disposition of:

3,997,346

(iv)

Shared power to dispose or to direct disposition of:

None

AEF LP

(a)

Amount Beneficially Owned:

By virtue of its ownership of 29.79% of the equity interest in AEMF, AEF LP may be deemed to beneficially own the 3,997,346 Shares of the Company’s Common Stock beneficially owned by ADMF.

Page 21 of 29 Pages

(b)

Percent of Class:

5.14%

(c)

Number of Shares as to which person has:

(i)

Sole power to vote or to direct vote:

3,997,346

(ii)

Shared power to vote or to direct vote:

None

(iii)

Sole power to dispose or direct disposition of:

3,997,346

(iv)

Shared power to dispose or to direct disposition of:

None

AEF LTD

(a)

Amount Beneficially Owned:

By virtue of its ownership of 57.28% of the equity interest in AEMF, AEF LTD may be deemed to beneficially own the 3,997,346 Shares of the Company’s Common Stock beneficially owned by ADMF.

(b)

Percent of Class:

5.14%

(c)

Number of Shares as to which person has:

(i)

Sole power to vote or to direct vote:

3,997,346

(ii)

Shared power to vote or to direct vote:

None

(iii)

Sole power to dispose or direct disposition of:

3,997,346

Page 22 of 29 Pages

(iv)

Shared power to dispose or to direct disposition of:

None

APA LP

(a)

Amount Beneficially Owned:

By virtue of its ownership of 4.46% of the equity interest in AEMF, APA LP may be deemed to beneficially own the 3,997,346 Shares of the Company’s Common Stock beneficially owned by ADMF.

(b)

Percent of Class:

5.14%

(c)

Number of Shares as to which person has:

(i)

Sole power to vote or to direct vote:

3,997,346

(ii)

Shared power to vote or to direct vote:

None

(iii)

Sole power to dispose or direct disposition of:

3,997,346

(iv)

Shared power to dispose or to direct disposition of:

None

Page 23 of 29 Pages

ATF LTD

(a)

Amount Beneficially Owned:

By virtue of its ownership of 2.18% of the equity interest in AEMF, ATF LTD may be deemed to beneficially own the 3,997,346 Shares of the Company’s Common Stock beneficially owned by ADMF.

(b)

Percent of Class:

5.14%

(c)

Number of Shares as to which person has:

(i)

Sole power to vote or to direct vote:

3,997,346

(ii)

Shared power to vote or to direct vote:

None

(iii)

Sole power to dispose or direct disposition of:

3,997,346

(iv)

Shared power to dispose or to direct disposition of:

None

AIEF LP

(a)

Amount Beneficially Owned:

By virtue of its ownership of 6.28% of the equity interest in AEMF, AIEF LP may be deemed to beneficially own the 3,997,346 Shares of the Company’s Common Stock beneficially owned by ADMF.

(b)

Percent of Class:

5.14%

Page 24 of 29 Pages

(c)

Number of Shares as to which person has:

(i)

Sole power to vote or to direct vote:

3,997,346

(ii)

Shared power to vote or to direct vote:

None

(iii)

Sole power to dispose or direct disposition of:

3,997,346

(iv)

Shared power to dispose or to direct disposition of:

None

BAM

(a)

Amount Beneficially Owned:

By virtue of its position as investment manager to each of ADMF, ADF LTD, ADF LP, AMF, AG, AGI, AEMF, AEF LP, AEF LTD, APA LP, ATF LTD and AIEF LP, BAM may be deemed to beneficially own the 4,408,952 Shares of the Company’s Common Stock beneficially owned by ADMF, ADF LTD, ADF LP, AMF, AG, AGI, AEMF, AEF LP, AEF LTD, APA LP, ATF LTD and AIEF LP.

(b)

Percent of Class:

5.67%

(c)

Number of Shares as to which person has:

(i)

Sole power to vote or to direct vote:

4,408,952

(ii)

Shared power to vote or to direct vote:

None

Page 25 of 29 Pages

(iii)

Sole power to dispose or direct disposition of:

4,408,952

(iv)

Shared power to dispose or to direct disposition of:

None

Dmitry Balyasny

(a)

Amount Beneficially Owned:

By virtue of his position as the sole control person for BAM, Mr. Balyasny may be deemed to beneficially own the 4,408,952 Shares of the Company’s Common Stock beneficially owned by BAM.

(b)

Percent of Class:

5.67%

(c)

Number of Shares as to which person has:

(i)

Sole power to vote or to direct vote:

4,408,952

(ii)

Shared power to vote or to direct vote:

None

(iii)

Sole power to dispose or direct disposition of:

4,408,952

(iv)

Shared power to dispose or to direct disposition of:

None

Item 5

Ownership of Five Percent or Less of a Class:

Applicable

Item 6

Ownership of More than Five Percent on Behalf of Another Person:

Not Applicable

Page 26 of 29 Pages

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

Not Applicable

Item 8

Identification and Classification of Members of the Group:

Not Applicable

Item 9

Notice of Dissolution of Group:

Not Applicable

Item 10

Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 27 of 29 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: December 3, 2021


ATLAS DIVERSIFIED MASTER FUND, LTD. By: /s/ Scott Schroeder Scott Schroeder Authorized Signatory		ATLAS MASTER FUND, LTD. By: /s/ Scott Schroeder Scott Schroeder Authorized Signatory

ATLAS DIVERSIFIED FUND, LTD. By: /s/ Scott Schroeder Scott Schroeder Authorized Signatory		ATLAS DIVERSIFIED FUND, L.P. By: /s/ Scott Schroeder Scott Schroeder Authorized Signatory

ATLAS GLOBAL, LLC By: /s/ Scott Schroeder Scott Schroeder Authorized Signatory		ATLAS GLOBAL INVESTMENTS, LTD. By: /s/ Scott Schroeder Scott Schroeder Authorized Signatory

ATLAS ENHANCED MASTER FUND, LTD. By: /s/ Scott Schroeder Scott Schroeder Authorized Signatory		ATLAS ENHANCED FUND, L.P. By: /s/ Scott Schroeder Scott Schroeder Authorized Representative

ATLAS PORTABLE ALPHA, LP By: /s/ Scott Schroeder Scott Schroeder Authorized Signatory		ATLAS TERRA FUND, LTD. By: /s/ Scott Schroeder Scott Schroeder Authorized Signatory

Page 28 of 29 Pages


ATLAS INSTITUTIONAL EQUITY FUND, L.P. By: /s/ Scott Schroeder Scott Schroeder Authorized Signatory		BALYASNY ASSET MANAGEMENT L.P. By: /s/ Scott Schroeder Scott Schroeder Authorized Signatory

DMITRY BALYASNY By: /s/ Scott Schroeder Scott Schroeder Authorized Representative

Page 29 of 29 Pages

Get the next $DRNA alert in real time by email

Date	Price Target	Rating	Analyst
12/9/2021	$28.00 → $38.25	Buy → Neutral	Chardan Capital
11/19/2021	$30.00 → $38.25	Outperform → Sector Perform	RBC Capital
11/18/2021	$32.00 → $38.25	Buy → Neutral	HC Wainwright & Co.
8/11/2021	$36.00 → $25.00	Buy → Neutral	Goldman Sachs
8/10/2021	$34.00 → $28.00	Buy	Chardan Capital
8/10/2021	$38.00 → $32.00	Buy	HC Wainwright & Co.
8/9/2021	$32.00	Buy → Neutral	Citigroup
8/6/2021	$35.00 → $30.00	Outperform	RBC Capital

NAMES OF REPORTING PERSONS

  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

  Atlas Diversified Master Fund, Ltd.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) ☐ (b) ☐

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman